Literature DB >> 15505391

Challenges for basic research in glutaryl-CoA dehydrogenase deficiency.

S Kölker1, K A Strauss, S I Goodman, G F Hoffmann, J G Okun, D M Koeller.   

Abstract

During the last decades, efforts have been made to elucidate the complex mechanisms underlying neuronal damage in glutaryl-CoA dehydrogenase deficiency. A combination of in vitro and in vivo investigations have facilitated the development of several hypotheses, including the probable pathogenic role of accumulating glutaric acid and 3-hydroxyglutaric acid. However, there are still many shortcomings that limit an evidence-based approach to treating this inborn error of metabolism. Major future goals should include generation of a suitable animal model for acute striatal necrosis, investigation of the formation, distribution and exact intra- and extracellular concentrations of accumulating metabolites, a deeper understanding of striatal vulnerability, and systematic investigation of effects on cerebral gene expression during development and of the modulatory role of inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505391     DOI: 10.1023/B:BOLI.0000045768.38073.22

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  38 in total

1.  Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.

Authors:  C Ikonomidou; F Bosch; M Miksa; P Bittigau; J Vöckler; K Dikranian; T I Tenkova; V Stefovska; L Turski; J W Olney
Journal:  Science       Date:  1999-01-01       Impact factor: 47.728

2.  Characterization of agonist-induced down-regulation of NMDA receptors in cerebellar granule cell cultures.

Authors:  A Resink; M Villa; D Benke; H Hidaka; H Möhler; R Balázs
Journal:  J Neurochem       Date:  1996-01       Impact factor: 5.372

Review 3.  Striatal degeneration and spongy myelinopathy in glutaric acidemia.

Authors:  D Soffer; N Amir; O N Elpeleg; J M Gomori; R S Shalev; S Gottschalk-Sabag
Journal:  J Neurol Sci       Date:  1992-02       Impact factor: 3.181

Review 4.  Glutaric aciduria type I and kynurenine pathway metabolites: a modified hypothesis.

Authors:  S Varadkar; R Surtees
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

5.  Biochemical, pathologic and behavioral analysis of a mouse model of glutaric acidemia type I.

Authors:  David M Koeller; Michael Woontner; Linda S Crnic; Bette Kleinschmidt-DeMasters; Janet Stephens; Edgar L Hunt; Stephen I Goodman
Journal:  Hum Mol Genet       Date:  2002-02-15       Impact factor: 6.150

6.  Conservation of central nervous system glutaryl-coenzyme A dehydrogenase in fruit-eating bats with glutaric aciduria and deficient hepatic glutaryl-coenzyme A dehydrogenase.

Authors:  T A McMillan; K M Gibson; L Sweetman; G S Meyers; R Green
Journal:  J Biol Chem       Date:  1988-11-25       Impact factor: 5.157

7.  Type I glutaric aciduria, part 2: a model of acute striatal necrosis.

Authors:  Kevin A Strauss; D Holmes Morton
Journal:  Am J Med Genet C Semin Med Genet       Date:  2003-08-15       Impact factor: 3.908

8.  3-Hydroxyglutaric acid induces oxidative stress and decreases the antioxidant defenses in cerebral cortex of young rats.

Authors:  Alexandra Latini; Rafael Borba Rosa; Karina Scussiato; Susana Llesuy; Adriane Belló-Klein; Moacir Wajner
Journal:  Brain Res       Date:  2002-11-29       Impact factor: 3.252

9.  Cloning, structure, and chromosome localization of the mouse glutaryl-CoA dehydrogenase gene.

Authors:  D M Koeller; K A DiGiulio; S V Angeloni; L L Dowler; F E Frerman; R A White; S I Goodman
Journal:  Genomics       Date:  1995-08-10       Impact factor: 5.736

10.  Selective potentiation of NMDA-induced neuronal injury following induction of astrocytic iNOS.

Authors:  S J Hewett; C A Csernansky; D W Choi
Journal:  Neuron       Date:  1994-08       Impact factor: 17.173

View more
  1 in total

1.  Orthopaedic manifestations of glutaric acidemia Type 1.

Authors:  Ahmet Imerci; Kevin A Strauss; Geovanny F Oleas-Santillan; Freeman Miller
Journal:  J Child Orthop       Date:  2020-10-01       Impact factor: 1.548

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.